• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/11/23 9:06:46 AM ET
    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPE alert in real time by email

    Gainers

    • Sunshine Biopharma (NASDAQ:SBFM) shares rose 45.1% to $0.77 during Thursday's pre-market session. The company's market cap stands at $17.3 million.
    • Jaguar Health (NASDAQ:JAGX) stock rose 28.19% to $0.92. The company's market cap stands at $12.7 million.
    • Ampio Pharmaceuticals (AMEX:AMPE) shares increased by 23.91% to $0.25. The company's market cap stands at $3.7 million.
    • Tivic Health Systems (NASDAQ:TIVC) stock rose 18.32% to $0.2. The company's market cap stands at $5.7 million.
    • PharmaCyte Biotech (NASDAQ:PMCB) stock increased by 15.69% to $3.17. The market value of their outstanding shares is at $55.2 million.
    • Assure Hldgs (NASDAQ:IONM) stock rose 15.33% to $1.88. The company's market cap stands at $2.0 million. As per the news, the Q1 earnings report came out yesterday.

    Losers

    • ImmunityBio (NASDAQ:IBRX) shares decreased by 54.5% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $1.2 billion.
    • Biophytis (NASDAQ:BPTS) shares decreased by 17.54% to $2.68. The market value of their outstanding shares is at $8.3 million.
    • CareDx (NASDAQ:CDNA) shares fell 17.35% to $7.1. The market value of their outstanding shares is at $381.9 million. As per the news, the Q1 earnings report came out yesterday.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares decreased by 16.42% to $0.56. The company's market cap stands at $121.6 million. As per the news, the Q1 earnings report came out yesterday.
    • Pharming (NASDAQ:PHAR) stock declined by 13.42% to $11.1. The market value of their outstanding shares is at $728.5 million. As per the press release, Q1 earnings came out today.
    • Vyant Bio (NASDAQ:VYNT) shares decreased by 12.5% to $0.33. The market value of their outstanding shares is at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMPE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPE
    $BPTS
    $CDNA
    $IBRX

    CompanyDatePrice TargetRatingAnalyst
    CareDx Inc.
    $CDNA
    1/6/2026$26.00Buy → Hold
    Craig Hallum
    CareDx Inc.
    $CDNA
    8/26/2025Mkt Perform
    William Blair
    ImmunityBio Inc.
    $IBRX
    5/20/2025$5.00Neutral → Overweight
    Piper Sandler
    ImmunityBio Inc.
    $IBRX
    3/6/2025$8.00Buy
    H.C. Wainwright
    CareDx Inc.
    $CDNA
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    ImmunityBio Inc.
    $IBRX
    1/10/2025$6.00Buy
    BTIG Research
    Pharming Group N.V. ADS each representing 10
    $PHAR
    12/9/2024$14.00Buy
    Jefferies
    CareDx Inc.
    $CDNA
    8/28/2024$28.00Underweight
    Wells Fargo
    More analyst ratings

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    SEC Filings

    View All

    SEC Form PRE 14A filed by PharmaCyte Biotech Inc.

    PRE 14A - PharmaCyte Biotech, Inc. (0001157075) (Filer)

    2/27/26 5:05:45 PM ET
    $PMCB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Leadership Update, Regulation FD Disclosure

    8-K/A - CareDx, Inc. (0001217234) (Filer)

    2/25/26 4:12:58 PM ET
    $CDNA
    Medical Specialities
    Health Care

    SEC Form 10-K filed by CareDx Inc.

    10-K - CareDx, Inc. (0001217234) (Filer)

    2/25/26 4:10:41 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Silverman Joshua bought $80,476 worth of shares (100,000 units at $0.80), increasing direct ownership by 32% to 416,250 units (SEC Form 4)

    4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

    1/7/26 5:43:33 PM ET
    $PMCB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Schechter Jonathan bought $48,232 worth of shares (60,000 units at $0.80), increasing direct ownership by 45% to 192,500 units (SEC Form 4)

    4 - PharmaCyte Biotech, Inc. (0001157075) (Issuer)

    1/7/26 5:43:16 PM ET
    $PMCB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    3/5/24 4:05:35 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 82,137 shares of common stock. The RSU awards were made pursuant to the Company's 2016 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, wit

    2/27/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

    Study fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG Interim analysis requested by the FDA demonstrated a statistically significant improvement in duration of complete response with ANKTIVA plus BCG, with no significant safety signals observed Company anticipates submitting a biologics license application (BLA) to the U.S. FDA by Q4 2026 Expanded access program (EAP) of recombinant BCG is ongoing, with 580 patients currently enrolled throughout the U.S. ImmunityBio ((IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANK

    2/26/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CareDx downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $26.00

    1/6/26 9:07:34 AM ET
    $CDNA
    Medical Specialities
    Health Care

    William Blair initiated coverage on CareDx

    William Blair initiated coverage of CareDx with a rating of Mkt Perform

    8/26/25 8:17:26 AM ET
    $CDNA
    Medical Specialities
    Health Care

    ImmunityBio upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded ImmunityBio from Neutral to Overweight and set a new price target of $5.00

    5/20/25 8:01:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Simon Barry J. sold $900,788 worth of shares (75,000 units at $12.01), decreasing direct ownership by 3% to 2,850,821 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/26/26 8:12:26 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Selecky Christobel exercised 25,000 shares at a strike of $2.98 and sold $250,000 worth of shares (25,000 units at $10.00) (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:58 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Soon-Shiong Patrick converted options into 114,329 shares and covered exercise/tax liability with 58,170 shares, increasing direct ownership by 0.19% to 29,757,911 units (SEC Form 4)

    4 - ImmunityBio, Inc. (0001326110) (Issuer)

    2/24/26 8:05:07 PM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

    Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BIb3649a77439d4a2d8e5e002bac980cd1 Once registered, dial-in information and a unique PIN will

    2/26/26 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

    CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference ca

    2/10/26 4:01:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Leadership Updates

    Live Leadership Updates

    View All

    CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

    Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac

    2/24/26 5:15:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

    Renowned Transplant Clinician to Lead CareDx Global Medical Affairs CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Jeffrey John Teuteberg, MD, as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of experience in clinical transplantation, including senior leadership roles at Stanford University and the University of Pittsburgh Medical Center. He is board certified in Heart Failure/Cardiac Transplantation

    10/27/25 7:05:00 AM ET
    $CDNA
    Medical Specialities
    Health Care

    $AMPE
    $BPTS
    $CDNA
    $IBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    SC 13G/A - CareDx, Inc. (0001217234) (Subject)

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pharming Group N.V. ADS each representing 10

    SC 13G/A - Pharming Group N.V. (0001828316) (Subject)

    11/14/24 6:17:36 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care